Spring Symposium | 2019

Spring Symposium 2019 focused on lung cancer research specifically. Instead of being viewed as monolithic disease, lung cancers are increasingly recognized as a collection of multiple different disease subtypes, each with its own genetic markers and corresponding therapeutic strategies. Even with targeted treatment, resistance to therapies can arise as a result of an evolutionary process among the mixed population of cancer cells, analogous to how bacterial infections gain resistant to antibiotics. In the advancement of personalized medicine, the treatment of lung cancer stands at the forefront. 

Among those in the vanguard leading the way are the symposium’s featured speakers: 

Aaron Hata, M.D., Ph.D. 
Evolution of Resistance to Targeted Therapies for Lung Cancer

Tyler Jacks, Ph.D. 
Engineering the Cancer Genome

Alice T. Shaw, M.D., Ph.D. 
Tumor Evolution and Heterogeneity in Lung Cancer